Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domperidone for Secondary Progressive Multiple Sclerosis
NCT02308137Phase 2Completed
- Sponsor
- University of Calgary
- Start
- Feb 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of domperidone in secondary-progressive multiple sclerosis (SPMS), sponsored by University of Calgary. Started Feb 2015; status: completed.
02
Drugs
domperidone
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT02308137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308137.